For people with heart disease, aiming for a specific 'bad cholesterol' level using adjustable statin doses works just as well over 3 years as starting with the strongest statin dose, when it comes to preventing heart attacks, strokes, or needing heart procedures. This finding is from the abstract summary - full study details were not available.
Evidence from Studies
Supporting (1)
Community contributions welcome
Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
The study tested whether aiming for a specific cholesterol range works as well as taking high-dose statins for heart disease patients, and found it does.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Definitively establish the overall effect size and consistency of the noninferiority of treat-to-target vs high-intensity statin strategies across diverse populations and healthcare settings.
A systematic review and meta-analysis of at least 5 randomized controlled trials comparing treat-to-target (LDL-C 50–70 mg/dL) vs fixed high-intensity statin (rosuvastatin 20 mg or atorvastatin 40 mg) in adults aged 40–80 with confirmed coronary artery disease, reporting 3-year composite cardiovascular outcomes, with risk of bias assessment and subgroup analyses by sex, diabetes status, and baseline LDL-C.
Provide high-quality causal evidence on whether treat-to-target strategies are noninferior or superior to high-intensity statins in reducing cardiovascular events.
A double-blind, multicenter RCT with 5000+ adults aged 50–75 with stable coronary artery disease, randomized to treat-to-target (LDL-C 50–70 mg/dL, using statin titration) vs fixed high-intensity statin (rosuvastatin 20 mg daily), followed for 5 years with adjudicated outcomes of death, MI, stroke, revascularization, and all-cause mortality, with blinded endpoint assessment and >90% follow-up.
Assess real-world effectiveness and long-term adherence patterns of treat-to-target vs high-intensity statin use in routine clinical practice.
A prospective cohort study of 10,000 patients with coronary artery disease from diverse healthcare systems, tracking those prescribed treat-to-target (with documented LDL-C monitoring and dose adjustments) vs fixed high-intensity statins, followed for 5 years for incident cardiovascular events, adjusting for age, sex, baseline LDL-C, diabetes, and medication adherence using pharmacy records.
Explore potential associations between statin strategy and rare adverse outcomes (e.g., statin-induced myopathy or diabetes) by comparing exposure history in cases vs controls.
A nested case-control study within a large electronic health record database, identifying 500 cases of statin-associated myopathy and 2000 matched controls among patients with coronary artery disease, comparing prior use of treat-to-target (with dose escalation) vs fixed high-intensity statins, adjusting for age, renal function, and concomitant medications.